Microtransponder Inc.

05/07/2026 | Press release | Distributed by Public on 05/07/2026 15:31

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Curnes Nelson Bunker
2. Date of Event Requiring Statement (Month/Day/Year)
05/07/2026
3. Issuer Name and Ticker or Trading Symbol
Mobia Medical, Inc. [MOBI]
(Last) (First) (Middle)
2802 FLINTROCK TRACE, SUITE 226
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
AUSTIN, TX 78738
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 19,427 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (1) (1) Common Stock 54,932 (1) D
Series C Preferred Stock (1) (1) Common Stock 28,710 (1) D
Series D Preferred Stock (1) (1) Common Stock 110,058 (1) D
Series E-1 Preferred Stock (1) (1) Common Stock 8,374 (1) D
Series F Preferred Stock (1) (1) Common Stock 81,821 (1) D
Series C Preferred Stock (1) (1) Common Stock 2,871 (1) I By Bridget Kelley Curnes Trust
Series C Preferred Stock (1) (1) Common Stock 2,871 (1) I By Evelyn Christine Curnes Trust
Series D Preferred Stock (1) (1) Common Stock 145,067 (1) I By Exceller Hunt Microtransponder 2017, LP
Series E-1 Preferred Stock (1) (1) Common Stock 78,171 (1) I By Exceller Hunt Microtransponder 2017, LP
Series E-2 Preferred Stock (1) (1) Common Stock 171,179 (1) I By Exceller Hunt Microtransponder 2017, LP
Series F Preferred Stock (1) (1) Common Stock 82,068 (1) I By Exceller Hunt Microtransponder 2017, LP
Warrants (2) 06/13/2033 Common Stock 6,890 $14.653 D
Warrants (2) 05/24/2033 Common Stock 6,794 $14.653 D
Convertible Notes (3) (3) Common Stock 175,077 (3) I By Curnes Fund 2001
Convertible Notes (3) (3) Common Stock 333,333 (3) I By Exceller Hunt Microtransponder 2017, LP
Stock Option (4) 12/14/2027 Common Stock 103,359 $3.73 D
Stock Option (5) 03/26/2030 Common Stock 38,553 $4.11 D
Stock Option (6) 03/26/2030 Common Stock 42,708 $4.11 D
Stock Option (7) 10/16/2035 Common Stock 34,037 $3.94 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Curnes Nelson Bunker
2802 FLINTROCK TRACE, SUITE 226
AUSTIN, TX 78738
Chief Financial Officer

Signatures

/s/ Chase Leavitt, Attorney-in-Fact 05/07/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each share of our Series A, Series C, Series D, Series E-1, Series E-2 and Series F Preferred Stock will convert into Common Stock immediately prior to the completion of the Issuer's initial public offering pursuant to its terms.
(2) The warrants are currently exercsisable. In connection with the Issuer's initial public offering (the "Offering"), the warrants will be exercised according to the terms of the applicable warrant agreement. The warrants have a net exercise provision under which the Reporting Person may, in lieu of payment of the exercise price in cash, surrender the warrants and receive a net amount of shares based on the fair market value of the shares at the time of exercise of the warrants after deduction of the aggregate exercise price.
(3) The Convertible Notes will automatically convert into Common Stock immediately prior to the closing of the Offering. The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
(4) The stock option is fully vested and exercisable.
(5) The stock option vested as to 25% of the underlying shares on March 11, 2025, and will vest thereafter in 36 substantially equal monthly installments.
(6) The stock option vested as to 25% of the underlying shares on March 5, 2026, and will vest thereafter in 36 substantially equal monthly installments.
(7) The stock option will vest as to 25% of the underlying shares on October 17, 2026, and will vest thereafter in 36 substantially equal monthly installments.

Remarks:
Exhibit 24 - Power of Attorney.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Microtransponder Inc. published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 07, 2026 at 21:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]